Should Value Investors Buy Avanos Medical (AVNS) Stock?

Zacks
Oct 09, 2024

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.

Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.

Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.

One stock to keep an eye on is Avanos Medical (AVNS). AVNS is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. The stock is trading with a P/E ratio of 13.11, which compares to its industry's average of 32.29. Over the past year, AVNS's Forward P/E has been as high as 21.37 and as low as 11.70, with a median of 13.46.

Investors should also note that AVNS holds a PEG ratio of 0.99. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. AVNS's industry currently sports an average PEG of 2.57. AVNS's PEG has been as high as 1.72 and as low as 0.97, with a median of 1.09, all within the past year.

Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. AVNS has a P/S ratio of 1.51. This compares to its industry's average P/S of 2.91.

Investors could also keep in mind Elekta (EKTAY), an Medical - Instruments stock with a Zacks Rank of # 2 (Buy) and Value grade of A.

Elekta also has a P/B ratio of 2.63 compared to its industry's price-to-book ratio of 4.32. Over the past year, its P/B ratio has been as high as 3.47, as low as 2.23, with a median of 2.79.

These are just a handful of the figures considered in Avanos Medical and Elekta's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that AVNS and EKTAY is an impressive value stock right now.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AVANOS MEDICAL, INC. (AVNS) : Free Stock Analysis Report

Elekta AB (EKTAY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10